Status:
COMPLETED
A Controlled Trial of Erenumab in Migraine Prevention
Lead Sponsor:
Amgen
Conditions:
Migraine
Eligibility:
All Genders
20-65 years
Phase:
PHASE3
Brief Summary
The purpose of this study was to assess the efficacy and safety of erenumab for prevention of migraine in Japanese adults with episodic migraine (EM) and chronic migraine (CM).
Detailed Description
Migraine prevention is an area of a large unmet medical need, with existing therapies often having modest efficacy and poor tolerability. Calcitonin gene-related peptide (CGRP) receptor antagonism is ...
Eligibility Criteria
Inclusion
- Subject has provided informed consent/assent prior to initiation of any study specific activities/procedures.
- Japanese subjects greater than or equal to 20 to less than or equal to 65 years of age upon entry into screening.
- History of migraine (with or without aura) for greater than or equal to 12 months before screening according to the International Headache Society Classification ICHD-3 (Headache Classification Committee of the International Headache Society, 2018) based on medical records and/or patient self-report
- Migraine frequency: Chronic Migraine (CM) or Episodic Migraine (EM) over the 3 months before screening based on the following criteria:
- CM is defined as greater than or equal to 15 headache days per month of which greater than or equal to 8 headache days on average across the 3 months meet criteria as migraine days
- EM is defined as less than 15 headache days per month of which at least 4 or more headache days on average across the 3 months meet criteria as migraine days
Exclusion
- Subjects greater than 50 years of age at migraine onset.
- History of cluster headache or hemiplegic migraine headache.
- Unable to differentiate migraine from other headaches.
- Migraine with continuous pain, in which the subject does not experience any pain-free periods (of any duration) during the 1 month before the screening period.
- Malignancy, except non-melanoma skin cancers, cervical or breast ductal carcinoma in situ within the last 5 years.
- Other exclusion criteria may apply
Key Trial Info
Start Date :
April 12 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 25 2020
Estimated Enrollment :
261 Patients enrolled
Trial Details
Trial ID
NCT03812224
Start Date
April 12 2019
End Date
November 25 2020
Last Update
February 21 2024
Active Locations (41)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Matsuyama, Ehime, Japan, 790-0925
2
Research Site
Kasuga-shi, Fukuoka, Japan, 816-0802
3
Research Site
Kasuga-shi, Fukuoka, Japan, 816-0824
4
Research Site
Hiroshima, Hiroshima, Japan, 730-0031